News from the partners – archive
![](https://amr-accelerator.eu/wp-content/uploads/2022/01/Partner_PrIMAVeRa_0000_ares.jpg)
26/07/22 – OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ Leuven
![](https://amr-accelerator.eu/wp-content/uploads/2022/07/Evotec.png)
06/07/22 – Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
![](https://amr-accelerator.eu/wp-content/uploads/2022/04/NICE.png)
12/04/22 – NICE reaches important milestone in the UK’s efforts to tackle antimicrobial resistance
![](https://amr-accelerator.eu/wp-content/uploads/2022/03/Uni-Dundee.png)
![](https://amr-accelerator.eu/wp-content/uploads/2019/04/LogoSantPau.png)
![](https://amr-accelerator.eu/wp-content/uploads/2023/07/Uni-Oxford-UCL.png)
![](https://amr-accelerator.eu/wp-content/uploads/2021/10/BEAM-Alliance.png)
21/10/21 – How the EU Pharmaceutical Strategy could help prevent the next pandemic
![](https://amr-accelerator.eu/wp-content/uploads/2021/08/DZIF.png)
![](https://amr-accelerator.eu/wp-content/uploads/2021/04/BioVersys.png)
14/04/21 – BioVersys receives €20 million in EU financing to support development of new antibiotics
![](https://amr-accelerator.eu/wp-content/uploads/2021/03/TB-Alliance.png)
30/03/21 – Astellas and TB Alliance Enter into a New Collaborative Research Agreement to Identify Lead Compounds for the Treatment of Tuberculosis
![](https://amr-accelerator.eu/wp-content/uploads/2021/02/BIOASTER.png)